TScan Therapeutics, Inc. has announced a strategic reorganization to prioritize its in vivo cell therapy program for solid tumors. The company will pause further enrollment in its Phase 3 ALLOHA-2 study of TSC-101 due to insufficient capital, though it will continue to track the 7 patients already enrolled on the treatment arm. Concurrently, the company is advancing two product candidates targeting PRAME and MAGE-A4 into IND-enabling studies, with plans to file its first IND in Q3 2027 and initiate Phase 1 development in Q4 2027.
In connection with the restructuring, TScan is reducing its workforce by approximately 75%. The company expects to complete the Strategic Reorganization by the end of the fourth quarter of 2026 and incur approximately $4.1 million in employee-related costs, primarily for pay continuation and benefits. The company also reported updated data from the Phase 1 ALLOHA study of TSC-101, noting that all 13 patients currently being tracked in Cohort C show complete donor chimerism, including two patients who relapsed and then converted to complete donor chimerism after receiving additional treatment.
Separately, the company received notice from The Nasdaq Stock Market LLC that its voting common stock failed to comply with the $1.00 minimum bid price rule. The company has been granted an initial compliance period of 180 calendar days, ending on February 23, 2027, to regain compliance. If the company does not meet this requirement, it may be afforded a second 180-day period to cure the deficiency, provided it transfers to the Nasdaq Capital Market.
Effective September 2, 2026, the company terminated the employment of Chief Financial Officer Jason A. Amello and Chief Medical Officer Chrystal Louis, M.D., MPH. Both were entitled to 12 months of base salary and COBRA premiums under their respective employment agreements. As part of the reorganization, CEO Gavin MacBeath, Ph.D., assumed the duties of principal financial officer and principal accounting officer.
